Inclusion of omalizumab in a trastuzumab desensitization protocol

Ester María Barreiro-Fernández; Manuel David Gil-Sierra; María del Pilar Briceño-Casado; Carmen Martínez-Díaz; Esmeralda Ríos-Sánchez

doi:10.7399/fh.11809

Inclusion of omalizumab in a trastuzumab desensitization protocol

Ester María Barreiro-Fernández, Manuel David Gil-Sierra, María del Pilar Briceño-Casado, Carmen Martínez-Díaz, Esmeralda Ríos-Sánchez

Resumen

Texto completo:

PDF (English) PDF

Referencias

Sangrador Pelluz C, Martínez García M, Pérez-Serrano Lainosa MD, Soler Company E. Protocolo de desensibilización a cisplatino. Farm Hosp. 2013;37(3):260-2. DOI: 10.7399/FH.2013.37.3.542

Cortijo-Cascajares S, Jiménez-Cerezo MJ, Herreros de Tejada A. Review of hypersensitivity reactions to antineoplastic agents. Farm Hosp. 2012;36(3):148-58. DOI: 10.1016/j.farma.2011.02.004

Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica de Xolair® 150 mg solución inyectable [Internet]. 2015 [accessed 13/07/2021]. Available at: https://cima.aemps.es/cima/dochtml/ft/05319008/FT_05319008.html

Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V, et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638-49. DOI: 10.1016/j.jaci.2017.06.032

Ojaimi S, Harnett PR, Fulcher DA. Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels. J Allergy Clin Immunol Pract. 2014;2(1):105-6. DOI: 10.1016/j.jaip.2013.08.009

Prieto-García A, Noguerado B, Rojas P, Torrado I, Rodríguez- Fernández A, Tornero P. Unexpected Anaphylaxis After Completing a Desensitization Protocol to Oxaliplatin: Successful Adjuvant Use of Omalizumab. J Investig Allergol Clin Immunol. 2019;29(1):53-5. DOI: 10.18176/jiaci.0326

Oude Elberink HNG, Jalving M, Dijkstra H, Van de Ven AAJM. Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study. Clin Transl Allergy. 2020;10:5. DOI: 10.1186/s13601-020-0309-0

Guillén D, Bobolea I, Calderón O, Fiandor A, Cabañas R, Heredia R, et al. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirinexacerbated urticaria and respiratory disease. J Investig Allergol Clin Immunol. 2015;25(2):133-5.

Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol. 2011;127(6):1622-4. DOI: 10.1016/j.jaci.2011.04.009

Briceño Casado MP, Martínez Díaz C, Salmerón Navas FJ, Camean Castillo M, García De Paredes Esteban JC, Gil Sierra, MD. Protocolo de desensibilización para brentuximab. Comunicación presentada en: 6.º Congreso de Oncología Médica, Hematología y Farmacia Oncohematológica. Toledo; 21-24 November 2018.

DOI: http://dx.doi.org/10.7399%2Ffh.11809